- Home
- BWLP vs RCUS Comparison
BWLP vs RCUS Comparison
Compare BWLP & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BWLP | RCUS |
|---|---|---|
| Founded | 1935 | 2015 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.8B |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BWLP | RCUS |
|---|---|---|
| Price | $24.36 | $30.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $31.90 |
| AVG Volume (30 Days) | 293.6K | ★ 1.1M |
| Earning Date | 05-19-2026 | 05-05-2026 |
| Dividend Yield | ★ 7.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $45.62 |
| P/E Ratio | $15.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.72 | $10.40 |
| 52 Week High | $25.48 | $31.74 |
Technical Indicators
Market Signals| Indicator | BWLP | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 60.83 | 59.62 |
| Support Level | $20.79 | $25.94 |
| Resistance Level | N/A | $31.41 |
| Average True Range (ATR) | 0.54 | 1.07 |
| MACD | 0.08 | 0.16 |
| Stochastic Oscillator | 62.03 | 78.79 |
Price Performance
Historical ComparisonAbout BWLP BW LPG Limited
BW LPG Ltd is an owner and operator of very large gas carriers. It operates in two segments: the Shipping segment, which includes LPG shipping and the Product Services segment, which includes the core shipping business. The Product Services segment derives the majority of the revenue.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.